Speakers and Agenda
(subject to change)
DAY 1, 06th April 2016
13.00: Registration, welcome coffee, networking and exhibition
13.55: Welcome and housekeeping
Session 1: Chair Dr Gregory Davis
14.00: Opening KEYNOTE: Professor Emmanuelle Charpentier, Director, Max Planck Institute for Infection Biology, Berlin, Germany
14.40: Dr Mark Behlke, Chief Scientific Officer, Integrated DNA Technologies, USA
Improved CRISPR editing using chemically-modified crRNA:tracrRNA complexes
15.10: Dr Annaleen Vermeulen, Senior Scientist, Dharmacon/GE Healthcare, Lafayette, CO, USA
Utilizing synthetic RNA for CRISPR-Cas9 arrayed screening
15.40: Refreshment break, networking, exhibition and posters
16.10: Dr Eric Paul Bennett, Associate Professor, Copenhagen Center for Glycomics (CCG), University of Copenhagen, Denmark
“Hit and seek”: Improved strategies for identifying the breaks in a precisely broken genome
16.40: Dr Stephen Hague, European Droplet Digital PCR Specialist, Bio-Rad Laboratories, UK
Ultra-sensitive Quantification of Genome Editing Events by Droplet Digital PCR (ddPCR)
17.10: Dr Kyle Luttgeharm, Application Specialist, Advanced Analytical Technologies Inc. 2450 SE Oak Tree Ct, Ankeny, IA, USA
Development of a high throughput screening protocol for rapid identification of mutated alleles
17.30: Dr Cornelia Hampe, Scientific Support Specialist, Takara Bio Europe, France
Gene editing with high efficiency and no additional footprint using novel CRISPR/Cas9 Gesicle technology
17.50: Technology Workshop 1 by Merck KGaA
18.20: Close of Day 1
DAY 2, 07th April 2016
08.45: Welcome to Day 2
Session 2: Chair Dr Mark Behlke
08.50: Dr Ben Davies, Transgenic Core Head and Group Leader, The Wellcome Trust Centre for Human Genetics, University of Oxford, UK
Efficient CRISPR/Cas9 genome engineering using embryos derived from Cas9 overexpressing transgenic mice
9.20: KEYNOTE: Dr Gregory Davis, Senior R&D Manager, MilliporeSigma, USA
Genome and Epigenome Modification with ZFNs and CRISPR/Cas Systems
10.00: Dr Chady Jaber, Thermo Fisher Scientific, UK
How to boost your CRISPR genome editing efficiencies
10.30: Refreshment break, networking, exhibition and posters
11.00: Dr Philip Webber, Patent Attorney, Dehns Patent and Trademark Attorneys, Oxford, UK
CRISPR – the Patent Wars
11.20: Dr Barry Rosen, Senior Principal Scientist, Discovery Sciences, AstraZeneca, UK (TBA)
11.50: Technology Workshop 2 by Merck KGaA
12.20: Technology Workshop 2 by Dr Barry Rosen and Colleagues
13.00: Lunch, networking, exhibition and posters
Session 3: Chair Dr Barry Rosen
14.00: KEYNOTE: Dr William C Skarnes, Senior Group Leader, The Wellcome Trust Sanger Institute, UK
Biallelic genome editing of human iPSCs at scale
14.45: Professor Richard Wade-Martins, Professor of Molecular Neuroscience & Principal Investigator, The Oxford Parkinson’s Disease Centre, University of Oxford, UK
Deciphering the molecular basis of neurodegeneration using human iPSC neurons
15.15: Dr Robin Ketteler, Group Leader, MRC Laboratory for Molecular Biology and Manager, Translational Research Resource Center, University College London, UK
Applications of Genome Editing and RNAi to Dissect Autophagy Signaling Pathways
15.45: Dr Christine Seidl, Research Associate, The Kennedy Institute of Rheumatology, University of Oxford, UK
Investigating functional microRNA target sites by CRISPR/Cas9 genome editing
16.15: Refreshment break, networking, exhibition and posters
17.00: Dr Tony Nolan, Senior Research Fellow, Imperial College London, UK
A CRISPR-based gene drive system to suppress populations of malarial mosquitoes
17.30: Dr Michal Minczuk, Group Leader, Mitochondrial Genetics, MRC Mitochondrial Biology Unit, Cambridge, UK
Manipulating the human mitochondrial genome with designer nucleases
18.00: Dr Aleksandar Vojta, Associate Professor, University of Zagreb, Faculty of Science, Zagreb, Croatia
Targeted CpG methylation using the modified CRISPR-Cas9 system
18.30: Close of Day 2
19.15: Networking Dinner (by prior booking or invitation only)
DAY 3, 08th April 2016
08.35: Welcome to Day 3
Session 4: Chair Dr Eric Paul Bennett
08.40: Dr Victor Dillard, Chief Operating Officer, Desktop Genetics, London, UK
Designing for success: the right CRISPR design strategies for the right experiment
09.00: Dr Lydia Teboul, Head of Molecular and Cellular Biology, MRC Harwell, UK
CRISPR-aided mutagenesis of the mouse genome
09.30: Dr Emmanouil Metzakopian, Career Development Fellow, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
Human and Mouse Genome Wide CRISPR-guide RNA Arrayed Libraries
10.00: Dr Fanny Decarpentrie, Postdoctoral Research Fellow, James TURNER group, Sex chrom in development & disease, The Francis Crick Institute, London, UK
New tool for new discoveries: CRISPR/Cas9 genome editing in marsupials
10.30: Refreshment break, networking, exhibition and posters
11.00: Dr Cedric Ghevaert, Senior Lecturer, Transfusion Medicine & Consultant Haematologist, University of Cambridge/Cambridge Blood Centre, UK
Platelet production in vitro for transfusion from human pluripotent stem cells: the added power of genome editing
11.30: Dr Cristina Fimiani, Graduate Researcher, SISSA, Trieste, Italy
RNA-therapeutics of gene haploinsufficiencies
11.50: Dr Hamid Dolatshad, Research Associate, RDM-Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
Use of CRISPR/CAS9 to investigate the function of gene mutations found in myeloid malignancies
12.20: Discussion and Close